30413048. 20. Zhang X, Yang J, Guo Y, Ye H, Yu C, et al. Functional proteomic analysis of nonalcoholic fatty liver illness in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology 51: 1190 1199. 21. Luo Z, Ma L, Zhao Z, He H, Yang D, et al. TRPV1 activation improves workout endurance and energy metabolism by means of PGC-1alpha upregulation in mice. Cell Res 22: 551564. 22. Delayre-Orthez C, Becker J, Guenon I, Lagente V, Auwerx J, et al. PPARalpha Gracillin cost downregulates airway inflammation induced by lipopolysaccharide MedChemExpress AVP inside the mouse. Respir Res 6: 91. 23. Panadero MI, Gonzalez MC, Herrera E, Bocos C Components modulating 
fibrates response: therapeutic implications and alternative approaches. Endocr Metab Immune Disord Drug Targets 9: 219236. 24. Schoonjans K, Staels B, Auwerx J The peroxisome proliferator activated receptors and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93109. 25. Patel DD, Knight BL, Wiggins D, Humphreys SM, Gibbons GF Disturbances inside the regular regulation of SREBP-sensitive genes in PPAR alphadeficient mice. J Lipid Res 42: 328337. 26. Gibbons GF, Patel D, Wiggins D, Knight BL The functional efficiency of lipogenic and cholesterogenic gene expression in normal mice and in mice lacking the peroxisomal proliferator-activated receptor-alpha. Adv Enzyme Regul 42: 227247. 27. Kim JB, Spotts GD, Halvorsen YD, Shih HM, Ellenberger T, et al. Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the standard helix-loop-helix domain. Mol Cell Biol 15: 25822588. 28. Adkins JC, Faulds D 
Micronised fenofibrate: a evaluation of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 54: 615633. 29. Martin PD, Dane AL, Schneck DW, Warwick MJ An open-label, randomized, three-way crossover trial on the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthful male volunteers. Clin Ther 25: 459471. 30. Nakajima T TN, Li G, Hu R, Kamijo Y, Hara A, et al. Impact of bezafibrate on hepatic oxidative anxiety: comparison involving traditional experimental doses and clinically-relevant doses in mice. Redox Rep 15: 123 130. 31. Knight BL, Hebbachi 23148522 A, Hauton D, Brown AM, Wiggins D, et al. A role for PPARalpha within the manage of SREBP activity and lipid synthesis inside the liver. Biochem J 389: 413421. 32. Gao M, Bu L, Ma Y, Liu D Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in higher fat diet-induced obese mice. PLoS One particular 8: e65641. 33. Search engine marketing YS, Kim JH, Jo NY, Choi KM, Baik SH, et al. PPAR agonists treatment is successful within a nonalcoholic fatty liver illness animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 23: 102109. 34. Cong WN, Tao RY, Tian JY, Liu GT, Ye F The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci 82: 983990. 35. Oosterveer MH, van Dijk TH, Tietge UJ, Boer T, Havinga R, et al. Higher fat feeding induces hepatic fatty acid elongation in mice. PLoS One 4: e6066. 36. Le Jossic-Corcos C, Duclos S, Ramirez LC, Zaghini I, Chevillard G, et al. Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes. Biochim Biophys Acta 1683: 4958. 37. Damiano F, Gnoni GV, Sicu.30413048. 20. Zhang X, Yang J, Guo Y, Ye H, Yu C, et al. Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology 51: 1190 1199. 21. Luo Z, Ma L, Zhao Z, He H, Yang D, et al. TRPV1 activation improves exercise endurance and power metabolism by means of PGC-1alpha upregulation in mice. Cell Res 22: 551564. 22. Delayre-Orthez C, Becker J, Guenon I, Lagente V, Auwerx J, et al. PPARalpha downregulates airway inflammation induced by lipopolysaccharide inside the mouse. Respir Res 6: 91. 23. Panadero MI, Gonzalez MC, Herrera E, Bocos C Things modulating fibrates response: therapeutic implications and option approaches. Endocr Metab Immune Disord Drug Targets 9: 219236. 24. Schoonjans K, Staels B, Auwerx J The peroxisome proliferator activated receptors and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93109. 25. Patel DD, Knight BL, Wiggins D, Humphreys SM, Gibbons GF Disturbances inside the normal regulation of SREBP-sensitive genes in PPAR alphadeficient mice. J Lipid Res 42: 328337. 26. Gibbons GF, Patel D, Wiggins D, Knight BL The functional efficiency of lipogenic and cholesterogenic gene expression in regular mice and in mice lacking the peroxisomal proliferator-activated receptor-alpha. Adv Enzyme Regul 42: 227247. 27. Kim JB, Spotts GD, Halvorsen YD, Shih HM, Ellenberger T, et al. Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid inside the simple helix-loop-helix domain. Mol Cell Biol 15: 25822588. 28. Adkins JC, Faulds D Micronised fenofibrate: a critique of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 54: 615633. 29. Martin PD, Dane AL, Schneck DW, Warwick MJ An open-label, randomized, three-way crossover trial from the effects of coadministration of rosuvastatin and fenofibrate around the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthier male volunteers. Clin Ther 25: 459471. 30. Nakajima T TN, Li G, Hu R, Kamijo Y, Hara A, et al. Effect of bezafibrate on hepatic oxidative pressure: comparison involving conventional experimental doses and clinically-relevant doses in mice. Redox Rep 15: 123 130. 31. Knight BL, Hebbachi 23148522 A, Hauton D, Brown AM, Wiggins D, et al. A part for PPARalpha within the manage of SREBP activity and lipid synthesis within the liver. Biochem J 389: 413421. 32. Gao M, Bu L, Ma Y, Liu D Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in higher fat diet-induced obese mice. PLoS A single 8: e65641. 33. Search engine optimization YS, Kim JH, Jo NY, Choi KM, Baik SH, et al. PPAR agonists therapy is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 23: 102109. 34. Cong WN, Tao RY, Tian JY, Liu GT, Ye F The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci 82: 983990. 35. Oosterveer MH, van Dijk TH, Tietge UJ, Boer T, Havinga R, et al. Higher fat feeding induces hepatic fatty acid elongation in mice. PLoS A single four: e6066. 36. Le Jossic-Corcos C, Duclos S, Ramirez LC, Zaghini I, Chevillard G, et al. Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes. Biochim Biophys Acta 1683: 4958. 37. Damiano F, Gnoni GV, Sicu.
